France is pulling back on its transition to a permanent medical cannabis regime. The switchover originally planned for the end of March 2026 has been postponed via correspondence from Health Minister Stéphanie Rist: the experimental pilot program will now continue until approximately the first quarter of 2027, with the final regulated system delayed to 2027, realistically 2028.
📑 Inhaltsverzeichnis
For patients who depend on the therapeutic properties of the cannabis plant, the extension provides planning certainty but lacks clarity. According to French sources, currently only around 700 individuals are receiving medical cannabis through the program, compared to approximately 3,200 between 2021 and 2024.
Pilot Phase Extended: What Paris Is Waiting For
The experimental phase, running since 2021, was supposed to expire at the end of March 2026 and transition into a permanent regulatory system. Instead, Health Minister Rist signed correspondence shortly before expiration, guaranteeing patient access through approximately Q1 2027. The reason: critical administrative steps remain outstanding.
Specifically, the decree proposal for the State Council is still missing—the responsible directorates DSS and DGS are expected to submit it in June 2026. The final assessment by the Haute Autorité de santé (HAS) is anticipated in October or November 2026. The earliest realistic date for regular prescriptions is therefore 2027, with further delays potentially pushing the launch to 2028.
Strict Requirements for Prescriptions and Cultivation
Unlike other European countries, France plans a highly pharmaceutical approach. Cannabis therapy is intended to remain defined as an ultima ratio—meaning it would only be used when standard conventional therapies fail or are not tolerated by patients.
Additionally, prescriptions should not be issued by any general practitioner. Only specially trained and certified physicians should be authorized to issue such prescriptions. On the production side, equally rigid requirements are planned. Outdoor or greenhouse cultivation would be strictly prohibited, and domestic producers would only be allowed to cultivate cannabis in strictly controlled indoor facilities and must demonstrate fixed contracts with authorized buyers in advance.
The Question of Reimbursement
A central point for the upcoming regime is cost coverage. During the pilot project, medical cannabis expenses were covered by the health insurance system. For the transition to the permanent system, authorities—particularly the French health authority—continue to negotiate over pricing structures and reimbursement models. The extension until 2027 now gives the administration time to align the enormous compliance requirements and medical oversight with sustainable production costs.
New Perspectives for the European Market
With the extended pilot phase, France establishes itself as one of the most heavily regulated, yet also forward-looking markets for medical cannabis in Europe. The strict separation of recreational use and purely medical application shows that Paris is taking a very controlled path. For patients, this primarily means product safety and standardized quality, while for companies it remains a challenge to overcome the high barriers to entry.
Looking at France demonstrates how differently the approaches to medical cannabis still vary across Europe in 2026. While the extension provides supply security for current patients, the central question remains open: whether the HAS assessment in fall 2026 will give the green light for regulated access. With a positive evaluation, estimates suggest that up to 400,000 patients could eventually gain access.
Correction Notice (April 21, 2026): In an earlier version, we stated that France would transition to a permanent medical cannabis regime beginning April 2026. In fact, the pilot phase has been extended until approximately the first quarter of 2027, with regulated access correspondingly delayed. We have updated the article in full. Our thanks to Aurélien Bernard from Newsweed.fr for the correction and the detailed original French report.
Sollte Medizinalcannabis nur als letzte Option verschrieben werden dürfen?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
